India GMP — Schedule M, Drugs and Cosmetics Rules
India's GMP requirements under the revised Schedule M of the Drugs and Cosmetics Rules, notified in December 2023. The revision introduces a formal pharmaceutical quality system, quality risk management, and computerised-system / data-integrity expectations, moving Indian GMP toward WHO/PIC-S norms.
What this does not cover
stated in the document's own scope- Covers GMP for the manufacture of pharmaceutical products; distribution and sale are governed by other parts of the Drugs and Cosmetics framework.
- Sets manufacturing GMP, not the drug-approval/registration decision, which follows the new-drug and import provisions of the Act and Rules.
- Prescribes the GMP requirement, not the analytical monographs, which come from the Indian Pharmacopoeia.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Schedule M sets India’s Good Manufacturing Practices requirements for pharmaceutical products, and a revised version was notified in December 2023. The revision modernises Indian GMP: it introduces a formal pharmaceutical quality system, quality risk management, and explicit computerised-system and data-integrity expectations, moving the requirements toward WHO and PIC/S norms. Schedule M prescribes the requirements for factory premises, plant and equipment, and the quality controls a licensed manufacturer must maintain, and it is enforced through India’s drug-licensing system administered by state licensing authorities alongside the central regulator, CDSCO.
Scope & applicability
Drug manufacturers in India. Implementation is phased — larger manufacturers first, with the MSME compliance deadline extended to 31 December 2025.
Legal basis & how it acquires force
Schedule M is a schedule to the Drugs and Cosmetics Rules, 1945, made under the Drugs and Cosmetics Act, 1940 — so it is subordinate legislation with the force of law, not guidance. Compliance with Schedule M is a condition of the manufacturing licence granted under the Rules, which means a manufacturer must meet it to be licensed to produce drugs in India. The revised Schedule M was notified by the Ministry of Health and Family Welfare in December 2023, with staged timelines for manufacturers to come into compliance.
Document structure
| Part | Covers |
|---|---|
| Pharmaceutical quality system | The quality management system, quality risk management, and product quality review |
| Premises and plant | General requirements for factory premises, layout, and services |
| Equipment and personnel | Plant and equipment requirements and personnel responsibilities and training |
| Documentation and records | The documentation system, master and batch records, and data-integrity controls |
| Production and quality control | Manufacturing operations, in-process control, and the quality-control function |
| Specific requirements | Additional parts covering particular product categories such as sterile products and biologicals |
Key requirements
- Implement a documented pharmaceutical quality system
- Apply quality risk management
- Meet data-integrity and computerised-system expectations
- Comply within the applicable phased deadline
Implementation tips
- Track each site's status against the phased Schedule M deadlines (MSME extension to 31 December 2025)
Revision notes
Revised Schedule M notified December 2023; large units required to comply in 2024, MSME deadline extended to 31 December 2025.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The 2023 revision deliberately moves Indian GMP toward the WHO GMP and PIC/S GMP Guide model, adding the pharmaceutical quality system, quality risk management and data-integrity expectations those texts carry. CDSCO (the Central Drugs Standard Control Organisation) is the national regulatory authority; the alignment narrows the gap between Schedule M and the international reference, though the binding requirement remains the Indian Rules as enforced under the country’s licensing system.
Revised Schedule M (2023): frequently asked questions
Quick answers to common questions about Revised Schedule M (2023).
Under what law does Schedule M sit?
Schedule M is part of the Drugs and Cosmetics Rules, 1945, made under the Drugs and Cosmetics Act, 1940. It is subordinate legislation with the force of law, and compliance is a condition of the manufacturing licence.
What did the 2023 revision of Schedule M change?
It introduced a formal pharmaceutical quality system, quality risk management, and explicit computerised-system and data-integrity expectations, moving Indian GMP toward WHO and PIC/S norms. It was notified in December 2023.
Which authority administers Schedule M?
India’s central regulator CDSCO works alongside state licensing authorities, which grant and oversee the manufacturing licences that require Schedule M compliance.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.